Stop Sepsis Through Home Monitoring Cooperative
Launched by UNIVERSITY HOSPITAL, ANTWERP · Apr 2, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The "Stop Sepsis Through Home Monitoring Cooperative" clinical trial is studying a new way to monitor patients who have severe infections and are at risk of developing a serious condition called sepsis. Instead of being constantly checked in a hospital, patients will wear devices that track their vital signs, like heart rate and temperature, from the comfort of their own homes. They will also use a special smartphone app for follow-up care. The goal is to see if this method can help patients avoid unnecessary hospital visits and stay healthier by getting quick help if their condition worsens.
To join the study, participants need to be at least 18 years old and show signs of a severe infection that could lead to sepsis. However, those who are very ill, confused, or have certain serious health conditions may not be eligible. By participating, individuals can expect regular monitoring and support while contributing to research that could improve future care for others at risk of sepsis. This innovative approach aims to make healthcare more efficient while ensuring that patients receive timely interventions when necessary.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • This study will include patients aged 18 years or older, capable of giving informed consent, presenting with signs of severe acute infection with a risk of developing sepsis at the emergency department or at their primary care physician.
- Exclusion Criteria:
- • Patients that are severely ill and require immediate hospitalization Qucik Sepsis Related Organ Failure score (QSOFA) ≥ 1 National Early Warning Score (NEWS) ≥ 5
- • Patients that demonstrate confusion, changes in mental state and/or an Mini-Mental State Examination (MMSE) below 26
- • Presence of neuropenic fever
- • Patients currently undergoing immunosuppressive therapy or chemotherapy
- • Patients with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
- • Suspicion of appendicitis, suspicion of meningitis or meningeal irritation, suspicion of or high risk of developing endocarditis
- • Complicated operation wounds at the time of screening
- • Proven pneumonia (CURB 65 score ≥ 1)
- • Emphysema, Chronic Obstructive Pulmonary Disease (COPD) GOLD \>1 or interstitial lung disease
- • Patients with oxygen at home \> 2 l/min on a chronic basis (severe underlying lung disease?)
- * Severe cardiovascular disease including:
- • Severe heart failure New York Heart Association (NYHA) class \> 1
- • Endoprosthesis
- • Cardiac arrhythmia including atrial fibrillation
- • Severe heart valve abnormalities
- • Mechanic valve replacement
- • Recent acute myocardial infarct or coronarography (less than 1y ago)
- • Severe peripheral vascular morbidity
- • Acute chest pain (suspicion of acute coronary pathology)
- • Suspicion of/chance of septic arthritis
About University Hospital, Antwerp
University Hospital Antwerp is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital fosters a collaborative environment that integrates cutting-edge scientific inquiry with state-of-the-art medical practices. As a prominent sponsor of clinical trials, University Hospital Antwerp is committed to enhancing medical knowledge and improving treatment outcomes across a wide range of specialties, leveraging its expertise to contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, Antwerpen, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported